Xeljanz Linked to Increased Risk of Blood Clots and Death
In Feb. 2019, the U.S. Food and Drug Administration (FDA) announced that patients who take a 10 mg twice-daily dose of tofacitinib (Xeljanz, Xeljanz XR) to treat rheumatoid arthritis (RA) are at a greater risk of blood clots in their lungs and death.
The FDA’s announcement came after an external data safety monitoring committee reviewed information from an ongoing clinical trial conducted by Pfizer, the drug’s manufacturer, and discovered the increased risks. The FDA’s currently approved dosage is 5 mg twice daily.
What Are the Symptoms of Xeljanz Injuries?
If you or someone you love takes Xeljanz, seek medical attention right away if you experience any of the following symptoms:
- Sudden shortness of breath or difficulty breathing
- Chest pain or back pain
- Coughing up blood
- Excessive sweating
- Clammy or bluish colored skin
Don’t stop taking Xeljanz without first speaking to your doctor, as doing so may put your health at risk.
We’re Here to Help After a Xeljanz Injury
Xeljanz is associated with serious injuries and complications, including blood clots in the lungs and even death. If you or a loved one suffered serious side effects after taking Xeljanz, including pulmonary embolism and deep vein thrombosis, you need legal representation for your drug injury-related expenses.
At Ferrer, Poirot & Wansbrough, it’s our goal to help drug injury victims like you get the money they deserve when dangerous medications cause serious harm. Contact our drug injury lawyers today—we’ll put our experience to work for you and your family.
Xeljanz® and Xeljanz XR® are registered trademarks of Pfizer Inc., and are used here only to identify the products in question. Ferrer, Poirot & Wansbrough is not associated with, sponsored by, or affiliated with Pfizer Inc. or the U.S. Food and Drug Administration.